AR025792A1 - Formulaciones orales de liberacion controlada - Google Patents

Formulaciones orales de liberacion controlada

Info

Publication number
AR025792A1
AR025792A1 ARP000105065A ARP000105065A AR025792A1 AR 025792 A1 AR025792 A1 AR 025792A1 AR P000105065 A ARP000105065 A AR P000105065A AR P000105065 A ARP000105065 A AR P000105065A AR 025792 A1 AR025792 A1 AR 025792A1
Authority
AR
Argentina
Prior art keywords
controlled release
oral formulations
releasing
pharmaceutical composition
therapeutically effective
Prior art date
Application number
ARP000105065A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR025792(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR025792A1 publication Critical patent/AR025792A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion farmacéutica capaz de liberar una dosis terapéuticamente efectiva del agente activo, por ejemplo rivastigmina, de una manera controlada enel tiempo.
ARP000105065A 1999-09-29 2000-09-27 Formulaciones orales de liberacion controlada AR025792A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923045.0A GB9923045D0 (en) 1999-09-29 1999-09-29 New oral formulations

Publications (1)

Publication Number Publication Date
AR025792A1 true AR025792A1 (es) 2002-12-11

Family

ID=10861819

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105065A AR025792A1 (es) 1999-09-29 2000-09-27 Formulaciones orales de liberacion controlada

Country Status (31)

Country Link
US (2) US20060246101A1 (es)
EP (1) EP1216032B1 (es)
JP (1) JP2003510268A (es)
KR (2) KR20050100710A (es)
CN (1) CN1213737C (es)
AR (1) AR025792A1 (es)
AT (1) ATE384517T1 (es)
AU (1) AU769646B2 (es)
BR (1) BR0014440A (es)
CA (1) CA2379595A1 (es)
CO (1) CO5210867A1 (es)
CY (1) CY1107923T1 (es)
CZ (1) CZ301455B6 (es)
DE (1) DE60037897T2 (es)
DK (1) DK1216032T3 (es)
EC (1) ECSP003685A (es)
ES (1) ES2299438T3 (es)
GB (1) GB9923045D0 (es)
HU (1) HUP0202744A3 (es)
IL (2) IL148908A0 (es)
MY (1) MY128759A (es)
NO (1) NO331480B1 (es)
NZ (1) NZ517335A (es)
PE (1) PE20010568A1 (es)
PL (1) PL200822B1 (es)
PT (1) PT1216032E (es)
RU (1) RU2281758C2 (es)
SK (1) SK286651B6 (es)
TR (1) TR200200683T2 (es)
WO (1) WO2001022944A1 (es)
ZA (1) ZA200202369B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
PL1789021T3 (pl) 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
MX364560B (es) * 2010-09-20 2019-05-02 Spi Pharma Inc Star Proceso de microencapsulacion y producto.
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
CN106000294B (zh) * 2016-07-04 2019-04-30 三峡大学 一种高膨胀低收缩率膨润土及制备方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US4984807A (en) * 1990-01-12 1991-01-15 Baruch Shiryon Board game
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
JP3950175B2 (ja) * 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system

Also Published As

Publication number Publication date
CZ20021028A3 (cs) 2002-06-12
BR0014440A (pt) 2002-06-18
CN1376058A (zh) 2002-10-23
DE60037897D1 (de) 2008-03-13
NO20021452D0 (no) 2002-03-22
WO2001022944A1 (en) 2001-04-05
IL148908A (en) 2010-06-16
NZ517335A (en) 2003-10-31
AU769646B2 (en) 2004-01-29
KR100661441B1 (ko) 2006-12-27
AU1019701A (en) 2001-04-30
PL354075A1 (en) 2003-12-15
NO20021452L (no) 2002-03-22
GB9923045D0 (en) 1999-12-01
DK1216032T3 (da) 2008-06-02
CN1213737C (zh) 2005-08-10
ATE384517T1 (de) 2008-02-15
JP2003510268A (ja) 2003-03-18
ECSP003685A (es) 2002-05-23
CY1107923T1 (el) 2013-09-04
HUP0202744A3 (en) 2004-05-28
CO5210867A1 (es) 2002-10-30
WO2001022944A8 (en) 2001-07-26
US20060246101A1 (en) 2006-11-02
IL148908A0 (en) 2002-09-12
DE60037897T2 (de) 2008-12-24
ZA200202369B (en) 2002-12-24
ES2299438T3 (es) 2008-06-01
PL200822B1 (pl) 2009-02-27
PT1216032E (pt) 2008-04-29
TR200200683T2 (tr) 2002-07-22
NO331480B1 (no) 2012-01-16
KR20050100710A (ko) 2005-10-19
CZ301455B6 (cs) 2010-03-10
RU2281758C2 (ru) 2006-08-20
CA2379595A1 (en) 2001-04-05
SK286651B6 (sk) 2009-03-05
KR20020038778A (ko) 2002-05-23
EP1216032B1 (en) 2008-01-23
US20110038897A1 (en) 2011-02-17
EP1216032A1 (en) 2002-06-26
PE20010568A1 (es) 2001-05-29
HUP0202744A2 (hu) 2003-01-28
MY128759A (en) 2007-02-28
SK4132002A3 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
ES2159591T3 (es) Composicion de liberacion controlada.
YU23402A (sh) Kompozicije sa kontrolisanim oslobađanjem koje sadrže nimezulid
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
SE0300831D0 (sv) New formulations and use therof
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
AP2003002763A0 (en) Controlled release formulations for oral administration
AR025792A1 (es) Formulaciones orales de liberacion controlada
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
ES2164310T3 (es) Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina.
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ES2175827T3 (es) Formulaciones transmucosas de levosimendano.
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.
ES2179658T3 (es) Uso de oxazolidinonas para la preparacion de un medicamento de suministro transdermico.
CL2007001675A1 (es) Procedimiento de preparacion de composiciones farmaceuticas en comprimidos, de desintegracion rapida y sustancialmente exentos de cristales del agente activo provenientes de la fabricacion, que comprende formar una masa granulada a partir del agente
MY145885A (en) Controlled release formulations for oral administration
GT199700112A (es) Nuevas microesferas farmaceuticas para administracion oral.
GT199600094A (es) Formulaciones farmaceuticas orales de liberacion prolongada
GT199900190A (es) Formulaciòn medicamentosa acuosa para administraciòn oral.-

Legal Events

Date Code Title Description
FB Suspension of granting procedure